U.S. Opioid Use Disorder Market Outlook Size Share Growth and Forecast to 2032

The article from Fortune Business Insights provides a comprehensive analysis of the U.S. opioid use disorder (OUD) market, which was valued at USD 2.36 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 9.9% through 2032. It highlights the increasing prevalence of opioid dependence, with approximately 2.7 million individuals in the U.S. reporting opioid dependence in 2021. Key trends include the rising adoption of buprenorphine patches as a treatment option, driven by their ease of use and self-administration capabilities. Government initiatives and NGO support are also contributing to market growth, particularly through reimbursement policies for opioid dependence treatments. The report identifies several driving factors, such as the expansion of opioid treatment programs and the introduction of new medications. However, it also notes challenges, including the adverse effects associated with opioid therapies, which may limit their adoption. Market segmentation is detailed by drug class (buprenorphine, methadone, naltrexone), route of administration (oral, parenteral), and distribution channels (hospital pharmacies, retail pharmacies, online pharmacies). The buprenorphine segment is highlighted as the largest and fastest-growing. Key industry players include Indivior PLC, Alkermes, and Orexo AB, with ongoing developments and partnerships aimed at enhancing treatment options and increasing awareness of opioid dependence. Report- Fortune Business Insights - U.S. Opioid Use Disorder [OUD] Market Size & Share, 2032 https://www.fortunebusinessinsights.com/u-s-opioid-use-disorder-oud-market-108778